Sphingosine-1-phosphate Receptor Subtype 1 Antagonists may be the Unmet Medical Need for Morphine-induced Hyperalgesia and Antinociceptive Tolerance
| Autor: | Y. Brik |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
business.industry Sphingosine-1-phosphate receptor Multiple sclerosis Central nervous system Chronic pain Pharmacology medicine.disease 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Anesthesiology and Pain Medicine Nociception medicine.anatomical_structure Hyperalgesia Morphine medicine medicine.symptom business 030217 neurology & neurosurgery S1PR1 medicine.drug |
| Zdroj: | Douleur et Analgésie. 34:191-194 |
| ISSN: | 1951-6398 1011-288X |
| DOI: | 10.3166/dea-2021-0165 |
| Popis: | Opioids such as morphine are frequently used for chronic pain management despite their many adverse effects. Ongoing research aims at either finding new treatments to replace opioids or reducing its heavy adverse effects due to long-term use: opioid-induced hyperalgesia and antinociceptive tolerance. In a recent study, Doyle et al. (2020) demonstrate that the activation of sphingosine-1-phosphate receptor subtype 1 (S1PR1) in the central nervous system contributes to morphine-induced hyperalgesia and antinociceptive tolerance in a rodent model of chronic pain. By targeting S1PR1 with molecules with functional antagonistic properties (some of which are FDA-approved for multiple sclerosis treatment), hyperalgesia and tolerance were significantly reduced without modifying morphine pharmacokinetics or efficacy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|